S-1/A: Cortigent IPO: Brain Implants for Vision & Stroke Recovery

Cortigent, a pioneer in neurostimulation, is launching an IPO to fund the development of its Orion artificial vision system and Stroke Recovery System, targeting significant unmet medical needs despite a history of operating losses.

Summary

• Cortigent is conducting an Initial Public Offering (IPO) of 1,500,000 shares of common stock at an anticipated price of $10.00 per share, aiming to raise approximately $12.92 million in net proceeds (or $14.99 million if the over-allotment option is fully exercised).
• The company is a pre-revenue entity with a history of recurring operating losses, reporting a net loss of $2.113 million for the nine months ended September 30, 2025, and $2.232 million for the year ended December 31, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern without additional funding.
• Proceeds from the IPO are earmarked for Orion research studies ($3 million), manufacturing for clinical trials ($4 million), Orion pivotal trial planning ($1 million), stroke recovery system research, and repayment of $1.5 million to its parent company, Vivani Medical, Inc.
• Cortigent's primary product candidates are the Orion Visual Cortical Prosthesis System for artificial vision and the Stroke Recovery System for improving arm and hand function in stroke patients.
• The Orion system completed a 6-year Early Feasibility Study in March 2025, showing significant improvements in visual function for participating subjects, and has FDA Breakthrough Device designation.
• The company targets commencing the Orion pivotal clinical trial in mid-2027, with an expected completion by mid-2029 and U.S. launch in late 2029.
• For the Stroke Recovery System, an Early Feasibility Study is targeted for mid-2027, followed by a pivotal trial in late 2028, with a potential launch in late 2030.
• The estimated total addressable market for Orion is approximately 82,000 profoundly blind Americans, representing a potential U.S. market of ~$4 billion, while the Stroke Recovery System could benefit up to 195,000 U.S. stroke victims annually, with a potential U.S. market of ~$6 billion.
• Cortigent possesses an extensive intellectual property estate, including 166 issued U.S. patents and 15 issued European patents, with some extending into 2038.
• Vivani Medical, Inc. will beneficially own approximately 77% of Cortigent's voting power post-IPO (74% if over-allotment exercised), making Cortigent a controlled company.

Sentiment

Score: 4

Explanation: While the company has promising technology and large addressable markets, its pre-revenue status, significant operating losses, going concern doubt, and long, uncertain clinical development timelines, coupled with the denial of a Breakthrough Device designation for its stroke system and reliance on future capital raises, indicate a high-risk investment profile. The IPO proceeds are critical but not sufficient for long-term operations.

Positives

• Successful completion of a 6-year Early Feasibility Study for the Orion Visual Cortical Prosthesis System in March 2025, demonstrating significant improvements in visual function (square localization, direction of motion, grating visual acuity) for participating subjects.
• The Orion system has received FDA Breakthrough Device designation, which is intended to accelerate medical device development, assessment, and review.
• Large estimated total addressable markets for both Orion (~$4 billion in the U.S. for 82,000 patients) and the Stroke Recovery System (~$6 billion in the U.S. for 195,000 patients).
• An extensive intellectual property portfolio includes 166 issued U.S. patents and 15 issued European patents, with some extending to 2038, covering core neurostimulation technologies.
• The company's predecessor, Second Sight, successfully navigated FDA approval for the Argus II system, demonstrating regulatory experience with Class III devices.
• The prior Argus II system exhibited high manufacturing standards and product reliability, with many patients using implants for over ten years.
• The neurostimulation platform technology has potential for multiple future applications beyond vision restoration and stroke recovery.
• Management has reached a tentative agreement with the FDA that the Functional Low-Vision Observer Rated Assessment (FLORA) is an adequate efficacy endpoint for an Orion pivotal study, subject to validation.

Negatives

• Cortigent is a pre-revenue company with a history of recurring operating losses since inception, including a net loss of $2.113 million for the nine months ended September 30, 2025, and $2.232 million for the year ended December 31, 2024.
• The company's financial condition creates substantial doubt about its ability to continue as a going concern.
• The Stroke Recovery System was denied Breakthrough Device designation by the FDA in June 2023, potentially leading to slower regulatory interactions.
• One serious adverse event (seizure) occurred in the Orion Early Feasibility Study, although it resolved safely and led to adjusted stimulation protocols.
• Three of the six Orion EFS subjects were explanted, limiting long-term data, though the reasons were deemed unrelated to device efficacy or safety by the independent medical safety monitor (IMSM).
• Approximately 100 of the company's issued U.S. patents will reach the end of their term by the end of 2029, potentially reducing intellectual property protection.
• The company has no large-scale manufacturing experience and relies on sole-source suppliers for critical components, posing risks to production and timelines.
• Reliance on Vivani for funding and services, with the Transition Funding, Support and Services Agreement having expired for ongoing funding obligations as of December 31, 2024, creates future funding uncertainty.
• New investors in the IPO will experience immediate and substantial dilution of $8.60 per share, as the offering price ($10.00) is significantly higher than the pro forma net tangible book value ($1.40).
• Vivani Medical, Inc. will retain approximately 77% of the voting power post-IPO, making Cortigent a 'controlled company' and exempting it from certain NYSE corporate governance requirements, which may reduce protections for other stockholders.
• An NIH grant application for the stroke recovery system was not initially awarded, adding uncertainty to non-dilutive funding for the program.
• The company has not yet received FDA agreement on the safety endpoints for an Orion pivotal trial, and validation of the FLORA assessment is still required.
• Cortigent needs to reestablish its ISO 13485:2016 certification and CE mark certification to market products in Europe, which have lapsed.

Risks

• Cortigent currently has no commercial products or product revenue and may never become profitable.
• Commercial and financial success depends on future products being accepted in the market, which is uncertain.
• Substantial competition from major medical device companies, academic institutions, and research institutions.
• Results of limited initial trials may not be predictive of future trial results, and ongoing development efforts may not demonstrate commercial feasibility.
• Clinical development of medical devices is a lengthy, expensive process with uncertain outcomes, and results of earlier studies may not be predictive of future trial results.
• Interim top-line and preliminary results from clinical trials may change as more patient data become available and are subject to audit and verification procedures.
• Requires substantial additional capital to support clinical trials and growth plans, which may not be available on acceptable terms, if at all, leading to dilution or hampering growth.
• May invest in or acquire other businesses, and business may suffer if unable to successfully integrate acquired businesses or manage growth.
• If capital is raised in the future by issuing equity or debt securities, existing stockholders may experience dilution, and new securities may have senior rights.
• Subject to litigation in the operation of business, with adverse outcomes potentially affecting business.
• Could be subject to future governmental investigations, inquiries, legal proceedings, and enforcement actions.
• Cortigent's predecessors have not been profitable, and operating losses are expected to continue for the foreseeable future.
• Any failure or delay in completing clinical trials or studies for new product candidates or next-generation products, and the expense of those trials, could adversely affect business.
• If Cortigent fails to recruit highly skilled personnel, its ability to identify, develop, and commercialize new products will be impaired.
• If Cortigent or its licensors are unable to protect intellectual property, financial condition, results of operations, and technology value could be adversely affected.
• Litigation or third-party claims of intellectual property infringement or challenges to patent validity would require resources and may prevent or delay development.
• If Cortigent fails to comply with obligations in licensing agreements (e.g., DEI agreement), it could lose important license rights.
• If Cortigent is unable to protect the intellectual property used in its products, others may copy innovations, impairing competition.
• May become involved in future lawsuits to protect or enforce patents, which could be expensive, time-consuming, and unsuccessful.
• Changes in patent laws or patent jurisprudence could diminish the value of patents.
• Obtaining and maintaining patent protection depends on compliance with various procedural and payment requirements, and non-compliance could reduce or eliminate protection.
• Enjoys only limited geographical protection with respect to certain patents and may not be able to protect intellectual property rights throughout the world.
• May be subject to damages from claims of wrongful use or disclosure of trade secrets or breach of non-competition agreements.
• Reliance on government funding and collaboration adds uncertainty and may impose requirements that increase costs.
• Increasingly dependent on sophisticated information technology systems, and failure to maintain data integrity or product malfunction could adversely affect business.
• Product liability lawsuits could divert resources, result in substantial liabilities, and reduce commercial potential.
• Legislative or regulatory reform of the healthcare system in the U.S. and foreign jurisdictions may adversely impact business.
• Subject to stringent domestic and foreign medical device regulation, and unfavorable regulatory action may materially and adversely affect financial condition.
• Revenue from product sales will be dependent upon pricing and reimbursement guidelines, and inadequate levels could cause operations to suffer.
• Even if regulatory clearance or approval is obtained, subject to ongoing requirements and inspections that could lead to restriction, suspension, or revocation of clearance.
• No large-scale manufacturing experience, which could limit growth.
• The price of common stock may be volatile, and the value of investment could decline.
• Securities have no prior trading market, and stock price may decline after the offering.
• Broad discretion in the use of proceeds, which may differ from estimates.
• Immediate and substantial dilution for new investors.
• No intention to pay dividends for the foreseeable future.
• Future sales and issuances of equity securities or rights to purchase equity securities would result in dilution.
• Certificate of Incorporation provides for Delaware Court of Chancery and federal courts as sole forums for certain disputes, limiting stockholders' ability to obtain a favorable judicial forum.
• Right to issue shares of preferred stock with rights, preferences, and privileges that may adversely affect common stock.
• Will incur increased costs as a result of being a publicly traded company.
• Operating in a period of economic uncertainty and capital markets disruption, impacted by geopolitical instability (Russia-Ukraine, Israel-Hamas conflicts).
• COVID-19 pandemic has had and can be expected to continue to have adverse effects on business and results of operations.
• Materials necessary to manufacture products may not be available on commercially reasonable terms, or at all.

Future Outlook

The company plans to commence a pivotal clinical trial for Orion in mid-2027, aiming for FDA clearance and U.S. launch in late 2029. For the Stroke Recovery System, an Early Feasibility Study is targeted for mid-2027, followed by a pivotal trial in late 2028, with a potential launch in late 2030. These timelines are contingent on adequate financing and FDA collaboration. The company also intends to reapply for a Breakthrough Device designation for the Stroke Recovery System and an NIH grant in early 2026.

Management Comments

• "We believe our 20-year history in developing neurostimulation for artificial vision with the Argus II system positions us well for expanded neurostimulation applications such as Orion and the stroke recovery system."
• "We believe that our 60-channel cortical stimulation device has the potential to target neuron populations more precisely and generate favorable clinical results [for stroke recovery]."
• "The timeline presented represents management's estimate of the time required to complete each stage. No assurance can be given that these timelines will prove correct."
• "Management has determined that the limited amounts of cash on hand raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued."

Industry Context

Cortigent operates in the highly competitive and rapidly evolving medical device industry, specifically neurostimulation for vision restoration and stroke rehabilitation. While it claims a unique competitive advantage with its platform technology, it faces competition from established medical device companies (e.g., MicroTransponder Inc. with Vivistim VNS), academic institutions, and innovative startups (e.g., Pixium Vision SA, Bionic Vision Technologies, Illinois Institute of Technology's ICVP, Neuralink Corp.). The industry is characterized by significant R&D, stringent regulatory hurdles (Class III devices), and the need for favorable reimbursement. Cortigent's focus on cortical implants for a broad range of blindness causes and targeted stroke recovery positions it against both retinal implant developers and brain-computer interface (BCI) companies, some of which are exploring similar vision restoration or motor control applications (e.g., Neuralink's BlindsightTM and PRIME study).

Comparison to Industry Standards

• Cortigent's Orion system is designed to treat a wider range of blindness causes by directly stimulating the visual cortex, bypassing diseased visual pathways, which differentiates it from retinal implants like the discontinued Argus II and Pixium Vision SA's PRIMA (sub-retinal implant).
• Competitors in visual prostheses include Pixium Vision SA (assets acquired by Science Corp., filing for EU approval for geographic age-related macular degeneration), Bionic Vision Technologies (Bionic Eye Visual Prosthesis System, planning pivotal trial), Nano Retina Inc. (retinal prostheses, clinical trial in Europe/Israel), Illinois Institute of Technology (Intracortical Visual Prosthesis penetrating electrode, Breakthrough Device designation, early feasibility study), and Neuralink Corp. (penetrating electrode cortical implant, Breakthrough Device designation for BlindsightTM for vision restoration, PRIME study for motor control).
• In medical device-assisted stroke rehabilitation, Cortigent's proposed 60-channel cortical stimulation device aims for more targeted direct cortical stimulation, which it expects to provide superior results compared to MicroTransponder Inc.'s FDA-approved Vivistim Vagus Nerve Stimulator (VNS).
• Cortigent's approach to stroke recovery builds on prior research by Northstar Neuroscience, Inc., which showed positive Phase 1 and 2 results with a single-channel device but failed a Phase 3 primary endpoint; Cortigent believes its 60-channel device can achieve more precise targeting and favorable clinical results.
• The Argus II system achieved Medicare reimbursement of approximately $150,000 per device, which Cortigent may seek to match or exceed for Orion, setting a benchmark for future reimbursement negotiations.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not party to any material legal proceedings.
• May be involved in legal proceedings or subject to claims incident to the ordinary course of business, which could have an adverse impact due to defense and settlement costs, diversion of resources, and other factors.

Related Party Transactions

• Vivani Medical, Inc. (parent company) contributed all of Second Sight's neurostimulation assets and operations to Cortigent in December 2022.
• Vivani guaranteed Cortigent's lease agreement for office space, effective March 1, 2023.
• Under the Transition Funding, Support and Services Agreement (March 2023, amended August 2023), Vivani advanced funds and provided services (salaries, rent, overhead) to Cortigent, covering operations from January 2023 through December 31, 2024, and continued funding until IPO completion.
• Cortigent is required to repay $1.5 million from IPO proceeds to Vivani.
• Cortigent will issue a five-year promissory note for $2 million at 5% annual interest to Vivani.
• Vivani agreed that Cortigent is not obligated to repay funding support payments exceeding a cumulative $3.5 million.
• Vivani provides the services of its Chief Operating Officer (Truc Le) and Chief Business Officer (Donald Dwyer) to Cortigent on an interim basis.
• Cortigent provides the services of its Chief Financial Officer (Edward Sedo) to Vivani; services provided by each party to the other before IPO completion are deemed equivalent in value and offset each other.
• As of December 31, 2024, Vivani provided $3.5 million in funding recorded as debt due to parent and an additional $3.5 million recorded as an investment in Net Parent Investment.
• Vivani will own approximately 77% of Cortigent's voting stock post-IPO (74% if over-allotment exercised), maintaining control over stockholder matters and certain corporate actions.
• Vivani has agreed to indemnify Cortigent for certain claims from the former business (Second Sight) before August 30, 2022.
• All transactions with affiliated parties are believed to be on terms favorable to Cortigent.

Stakeholder Impact

• **Shareholders (New Investors)**: Will experience immediate and substantial dilution ($8.60 per share) and face high investment risk due to the company's pre-revenue status, operating losses, and going concern doubt. Voting power will be significantly diluted by Vivani's controlling stake.
• **Shareholders (Vivani Medical, Inc.)**: Will retain majority voting control (approximately 77% post-IPO) and receive $1.5 million repayment and a $2 million promissory note from IPO proceeds, solidifying its financial position relative to Cortigent.
• **Employees**: The current six full-time employees will continue, with plans to hire additional staff. Executive officers and directors will receive stock options post-IPO. Past workforce reductions (March/April 2020, October 2023) indicate potential for future staffing adjustments based on funding and development progress.
• **Customers/Patients**: Potential for new medical devices (Orion, Stroke Recovery System) to address profound blindness and stroke-induced paralysis, offering improved quality of life, but subject to successful clinical trials, regulatory approvals, and reimbursement, which are long-term and uncertain.
• **Suppliers**: Reliance on sole-source suppliers for critical components poses risks to manufacturing timelines and costs, potentially impacting product availability.
• **Creditors**: Vivani is a significant creditor, with $3.5 million owed, partially to be repaid by IPO proceeds and a promissory note. The company's going concern doubt could impact its ability to secure future debt financing from other sources.

Next Steps

• Manufacture and validate new Orion devices for a planned pivotal clinical trial.
• Commence Orion pivotal clinical trial in mid-2027, involving approximately 60 profoundly blind patients at approximately 10 U.S. trial sites.
• Complete Orion pivotal trial by mid-2029.
• Obtain FDA clearance for Orion and launch in the U.S. in late 2029.
• Manufacture modified clinical trial devices for the Stroke Recovery System Early Feasibility Study (EFS).
• Commence Stroke Recovery System EFS in mid-2027.
• Commence Stroke Recovery System pivotal clinical trial in late 2028.
• Complete Stroke Recovery System pivotal trial by mid-2030.
• Launch Stroke Recovery System in late 2030.
• Work with the FDA to gain agreement on additional clinical studies and safety endpoints for Orion.
• Conduct a patient preference information (PPI) study for Orion to assist in determining blind patients' willingness to accept risk for potential benefits.
• Reapply for Breakthrough Device designation for the Stroke Recovery System once clinical data supporting the novel approach are acquired.
• Reapply for NIH grant funding for the stroke recovery program in early 2026.
• Engage two U.S.-based contract manufacturing organizations (CMOs) to produce both the Orion and the stroke recovery system for upcoming clinical trials after completing the current offering.
• Adopt a written related person transaction policy upon consummation of the offering.
• File one or more registration statements on Form S-8 under the Securities Act to register shares issued or reserved for future issuance under the equity incentive plan.
• Obtain product liability insurance prior to the closing of the offering.
• Reestablish ISO 13485:2016 certification and CE mark certification to market products in Europe.

Key Dates

Recommendation

Cortigent is a pre-revenue company with a history of significant operating losses and a stated "substantial doubt" about its ability to continue as a going concern. While its neurostimulation technology for artificial vision and stroke recovery shows promise in early studies and addresses large unmet medical needs, the path to commercialization is long, expensive, and highly uncertain, with pivotal trials not expected to complete until 2029-2030. The denial of Breakthrough Device designation for its stroke system and the uncertainty of future NIH grants add to the risk. New investors will face immediate and substantial dilution, and the company's "controlled company" status limits corporate governance protections. Given the high financial risk, long development timelines, and current lack of revenue, a seasoned investor would likely view this as a highly speculative investment with significant downside risk, warranting a "sell" or "strong sell" if already held, or avoiding purchase.

Keywords

Neurostimulation, Brain Implant, Artificial Vision, Stroke Recovery, Medical Device, IPO, SEC Filing, Orion System, Cortical Prosthesis, FDA Breakthrough Device, Clinical Trials, Biotechnology, Healthcare, Intellectual Property, Going Concern, Vivani Medical, CRGT